Driver and actionable mutations in younger patients with lung cancer-are we searching properly?

Logo poskytovatele

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

BRATOVÁ Monika BRAT Kristián PAVLOVSKÝ Zdeněk ŠÁNA Jiří SLABÝ Ondřej

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj Biomedical Papers, Olomouc: Palacky University
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3379
Doi http://dx.doi.org/10.5507/bp.2023.012
Klíčová slova lung cancer; young patient; driver; mutation
Přiložené soubory
Popis Aims.The authors focused on a group of young lung cancer patients with the aim of better understanding the mechanisms of tumor pathogenesis in these patients and search for potential targetable mutations.Methods. We collected retrospective data on patients under 40 years diagnosed with lung cancer (NSCLC or small-cell lung cancer) from 2011-2020 at the Department of Respiratory Diseases, University Hospital Brno, Czech Republic. Tumor tissue of these patients was analysed by next-generation sequencing (NGS, a panel of 550 variants in 19 genes). Demographic characteristics, smoking history, histology, molecular-genetic results and clinical stage of the disesase were recorded in all eligible patients from accessible medical databases.Results. Of 17 identified patients in only 8 cases was successful NGS carried out due to lack of sufficient good quality material in the other cases. The most frequently found molecular genetic changes were EGFR, RICTOR and HER2 amplification and MET and FGFR1 amplification. In addition, we found rare pathogenic variants in BRAF and PIK3CA genes. Actionable variants were detected in 75% patients.Conclusion. We detected very frequent driver and potentially actionable alterations in young patients with lung cancer. This suggests different mechanisms of carcinogenesis in these patients and indicates that they might benefit more from a specific approach than older lung cancer patients.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.